{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"layer_decay_and_expiration_management__pharmacology_toxicology","archetype_slug":"layer_decay_and_expiration_management","domain_slug":"pharmacology_toxicology","title":"Indication-Aware Reversible Medication Lifecycle Management","opportunity_summary":"Convert episodic medication reconciliation into a clinician-governed lifecycle that flags therapies with absent or outdated justification, supports monitored refresh, taper, pause, or discontinuation decisions, and preserves reconstructable history. The proposal addresses a plausible safety problem, but its prevalence, comparative benefit, and distinctiveness remain unverified.","adopter_authorizer":"A participating outpatient practice or health-system medication-safety program could adopt the workflow; each change remains authorized by the patient and appropriately licensed prescriber, with pharmacist and relevant-specialist input.","scores":{"meaningful_impact":{"score":4,"rationale":"If stale therapies materially occur, reducing avoidable toxicity, interaction burden, prescribing cascades, and regimen complexity while preventing unsafe withdrawal would be consequential. The candidate supplies credible harm pathways, but their frequency and preventable share are unverified."},"stakeholder_pull":{"score":3,"rationale":"Patients, prescribers, pharmacists, and medication-safety leaders have proposal-specific reasons to value clearer justification and safer deprescribing, but the sealed candidate contains no evidence of expressed demand, workflow willingness, or budget ownership."},"incremental_advantage":{"score":3,"rationale":"Scheduled revalidation, explicit lifecycle states, dependency gates, rollback planning, and preserved supersession history plausibly improve upon opportunistic reconciliation and a one-time pharmacist review. Comparative effectiveness and added workload are untested."},"distinctiveness_plausibility":{"score":2,"rationale":"The combined lifecycle-state and reversible-deprescribing structure is coherent, but prior art is explicitly unsearched. The sealed material cannot establish that this combination differs meaningfully from existing deprescribing or longitudinal medication-management approaches."},"technical_implementability":{"score":3,"rationale":"The workflow uses recognizable medication records, clinician review, monitoring, and audit fields, making a bounded pilot plausible. Fragmented indication provenance, unsynchronized systems, dependency inference, and time-sensitive rescue limit confidence."},"adoption_authority_feasibility":{"score":3,"rationale":"Treatment authority, affected parties, exclusions, and halt rules are clearly specified. Feasibility remains mixed because responsibility can be fragmented across prescribers and the workflow requires patient participation, specialist coordination, and reliable follow-up."},"evidence_readiness":{"score":4,"rationale":"The candidate defines separate problem and intervention falsifiers, a nearest rival, measurable justification and burden outcomes, safety outcomes, and a bounded outpatient-panel setting. Baseline rates, measurement definitions, and data quality still require validation."},"safety_net_benefit":{"score":4,"rationale":"One-medication-at-a-time changes, prespecified follow-up, patient-request halts, rescue or restart plans, and retained history provide substantial safeguards relative to unstructured removal. These safeguards cannot eliminate nonlinear withdrawal or relapse risk or compensate for rescue slower than the harm window."},"scalability":{"score":3,"rationale":"A common lifecycle model and scheduled revalidation could be reused across panels and organizations, but scaling depends on interoperable histories, accurate ownership, sufficient pharmacist and prescriber capacity, synchronized medication lists, and equitable documentation quality."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"A bounded shadow-mode study in one outpatient panel comparing lifecycle-based review with the stated one-time pharmacist review, using clinician adjudication and no protocol-directed medication changes.","confidence":"MODERATE","assumptions":["Existing medication and encounter records can be accessed under local governance.","The study includes data extraction, pharmacist and prescriber review, adjudication, analysis, compliance work, and patient-record privacy controls.","No new enterprise software integration or live treatment automation is included."]},"initial_deployment_startup":{"band_2026_usd":"250K_TO_1M","scope":"Startup for one organization, including lifecycle-field configuration, medication-history integration, clinical governance, exception and rollback protocols, training, privacy review, and evaluation setup.","confidence":"LOW","assumptions":["The organization has an adaptable longitudinal medication-record system.","Automation is limited to identification and prioritization.","Substantial custom interoperability work, regulatory submissions, and new monitoring equipment are not required."]},"operational_launch":{"band_2026_usd":"1M_TO_5M","scope":"Controlled launch across multiple outpatient clinics within one health system, including integration hardening, clinical staffing, patient communication, monitoring capacity, support, safety oversight, and comparative evaluation.","confidence":"LOW","assumptions":["Launch remains clinician-governed and excludes automatic discontinuation.","Existing pharmacy, laboratory, and clinical follow-up services can absorb part of the monitoring workload.","The range could increase materially if records are fragmented or specialist coordination requires dedicated personnel."]},"annual_recurring":{"band_2026_usd":"250K_TO_1M","scope":"Annual operation within one health system for pharmacist and prescriber review time, revalidation queues, follow-up, rescue coordination, software support, audit, privacy controls, training, and safety monitoring.","confidence":"LOW","assumptions":["Clinical volume is moderate and the workflow prioritizes rather than reviews every drug continuously.","Core infrastructure already exists after startup.","The sealed candidate provides no utilization, staffing, or alert-volume data."]}},"research_burden":"HIGH","earliest_credible_horizon":"3_TO_12_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"YES","reason":"The candidate specifies an observable, falsifiable condition: active drugs lacking current documented indication, reassessment, ownership, or an explanation for continuation, together with plausible toxicity and unsafe-discontinuation consequences."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"An outpatient practice or health-system medication-safety program is an identifiable adopter, while the patient and licensed prescriber are explicitly identified as treatment authorizers, supported by pharmacists and relevant specialists."},"distinct_testable_incremental_claim":{"status":"YES","reason":"The proposal can be compared with one-time pharmacist review on current-justification coverage, avoidable regimen burden, clinician actionability, patient burden, withdrawal, destabilization, and serious adverse events."},"bounded_next_evidence_step":{"status":"YES","reason":"One outpatient panel can undergo a time-bounded shadow comparison of lifecycle review and one-time pharmacist review, with clinician adjudication and no medication changes required to test prevalence, data reliability, and incremental candidate detection."},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"The candidate preserves patient and licensed-prescriber authority, prohibits automatic or abrupt discontinuation, and supplies individual and pilot-level halt and rescue conditions. Residual clinical risks require monitoring but do not prevent a non-interventional first study."},"implementation_cost_scope_and_range":{"status":"YES","reason":"The sealed candidate identifies a one-panel starting scope and the required records, clinical roles, monitoring, coordination, and safeguards, allowing broad resource-equivalent bands to be bounded, although exact costs remain unverified."}},"blocking_evidence":["The proportion of active therapies in the target population that truly lack current justification, rather than merely having fragmented documentation, is unknown.","Medication identity, indication provenance, ownership, dependency, and reassessment fields may be too incomplete or unsynchronized for reliable flagging.","Incremental yield and actionability versus a one-time pharmacist review have not been demonstrated.","Comparative effects on toxicity, regimen burden, withdrawal, disease control, serious adverse events, and patient-reported burden are unknown.","Clinician capacity, cross-prescriber coordination, follow-up timeliness, and rescue speed have not been established.","Differential documentation quality could produce inequitable or systematically inaccurate flagging.","Prior art and the proposal's distinctiveness from existing deprescribing and longitudinal medication-management approaches are unsearched and unverified."],"next_evidence_step":"Run an 8- to 12-week shadow-mode study on one outpatient panel: independently apply the proposed lifecycle review and the nearest-rival one-time pharmacist review, then have licensed clinicians adjudicate current justification, ownership, dependency risk, and actionability without protocol-directed medication changes. Proceed only if the lifecycle method adds reproducible actionable information without unacceptable false flags or review burden; falsify the problem if nearly all drugs already have current justification and ownership, and falsify incremental value if the method does not outperform the rival on prespecified justification coverage or avoidable-burden detection.","research_questions":["How often does adjudication confirm unjustified continuation rather than missing or fragmented documentation?","Which lifecycle fields can be recovered reliably from existing records, and what inter-reviewer agreement is achieved?","Does the lifecycle method add actionable candidates or clearer rationales beyond one-time pharmacist review?","What false-positive rate, review time, alert burden, and coordination burden result?","Can monitoring and rescue occur within the plausible withdrawal, rebound, or relapse window for each medication class considered?","Do supervised one-medication changes improve justification or regimen burden without worsening disease control, withdrawal, serious adverse events, or patient-reported burden?","Does documentation quality create differential flagging across patient populations or care settings?","Which elements of the proposed mechanism composition, if any, are absent from prior implementations?","What organization owns the recurring workflow and budget while preserving individual treatment authority?"],"recommendation":"PRIOR_ART_RESEARCH","uncertainty_constraints":["Closed-book assessment cannot establish problem prevalence, stakeholder demand, market size, realized clinical impact, comparative effectiveness, or exact cost.","Medication count and therapy age are not valid proxies for net harm; expiration may trigger review only.","Incomplete indication documentation may reflect record fragmentation rather than unjustified therapy.","Physiological effects can be nonlinear and time-sensitive, so retained history does not guarantee successful reconstruction of disease control.","Cost bands are resource-equivalent planning ranges based on the described scope, not observed prices or implementation quotes.","Novelty and distinctiveness cannot be scored favorably without external comparison."],"closed_book_prior_art_boundary":"Prior art is unsearched and unverified. This closed-book assessment supports only the proposal's internal structural coherence and does not establish novelty, prevalence, market position, or superiority over existing deprescribing, medication-reconciliation, or longitudinal medication-management approaches."}